key: cord-0995478-mpeugvt9 authors: Valdes-Balbin, Yury; Santana-Mederos, Darielys; Quintero, Lauren; Fernández, Sonsire; Rodriguez, Laura; Ramirez, Belinda Sanchez; Perez, Rocmira; Acosta, Claudia; Méndez, Yanira; Ricardo, Manuel G.; Hernandez, Tays; Bergado, Gretchen; Pi, Franciscary; Valdes, Annet; Carmenate, Tania; Ramirez, Ubel; Oliva, Reinaldo; Soubal, Jean-Pierre; Garrido, Raine; Cardoso, Felix; Landys, Mario; Gonzalez, Humberto; Farinas, Mildrey; Enriquez, Juliet; Noa, Enrique; Suarez, Anamary; Fang, Cheng; Espinosa, Luis A.; Ramos, Yassel; González, Luis Javier; Climent, Yanet; Rojas, Gertrudis; Relova-Hernández, Ernesto; Infante, Yanelys Cabrera; Losada, Sum Lai; Boggiano, Tammy; Ojito, Eduardo; Monzon, Kalet Leon; Chiodo, Fabrizio; Paquet, Françoise; Chen, Guang-Wu; Rivera, Daniel G.; Garcia-Rivera, Dagmar; Verez-Bencomo, Vicente title: SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies date: 2021-03-02 journal: bioRxiv DOI: 10.1101/2021.02.08.430146 sha: dbad049656537d8f5bd64602162ed93eb00a817a doc_id: 995478 cord_uid: mpeugvt9 Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to use neutralizing antibodies to block viral sites binding to the host’s cellular receptors. Virus infection is mediated by the spike glycoprotein trimer on the virion surface via its receptor binding domain (RBD). Antibody response to this domain is an important outcome of the immunization and correlates well with viral neutralization. Here we show that macromolecular constructs with recombinant RBD conjugated to tetanus toxoid induce a potent immune response in laboratory animals. Some advantages of the immunization with the viral antigen coupled to tetanus toxoid have become evident such as predominant IgG immune response due to affinity maturation and long-term specific B-memory cells. This paper demonstrates that subunit conjugate vaccines can be an alternative for COVID-19, paving the way for other viral conjugate vaccines based on the use of small viral proteins involved in the infection process. Control of SARS-CoV-2 infection focuses on development of preventive vaccines. 1 Viral particles' initial binding is mediated by the receptor binding domain (RBD) of the spike (S)glycoprotein trimer to the host's cell surface receptor, the angiotensin-converting enzyme 2 (ACE2). [2] [3] [4] [5] Most of the 200 COVID-19 vaccines in development 6 aim to block this process. 1 By focusing on the whole S-protein or its RBD as antigen, the primary goal is induction of anti-RBD antibodies that interfere with RBD-ACE2 interaction, blocking the first step of infection. Virus neutralization is mainly associated with antibodies against the receptor binding motif (RBM), a specific RBD region directly interacting with ACE2. 7 This type of antibodies are not involved in antibody dependent enhancement (ADE). 8 Key advantages of the well-known recombinant subunit vaccine platforms are their safety, stability at 2-8 o C and facility to scale-up the production. 9 While we should expect weak immunogenicity for such a small recombinant RBD protein (30 kDa), requiring repeated vaccination, 10 it was found that recombinant RBD in alum is sufficient to induce a neutralizing immune response in laboratory animals, 11 while its simplicity prompted subsequent evaluation in humans. 12 However, most recombinant vaccines relied on large, RBD-containing macromolecular constructs as a way to increase the immunogenicity and on the use of potent adjuvants. 13 In addition to the lower immunogenicity, small recombinant RBD exposes to the immune system not only the critical RBM surface but also RBD regions that are well-camouflaged at the virus surface. Antibodies directed to camouflaged RBD regions are not neutralizing, and therefore, an 4 ideal construction should maximize the exposure of the RBM and not of such regions. We hypothesized that the orientation of RBD when conjugated to tetanus toxoid, exposes better the RBM surface increasing the level of neutralizing antibodies. [14] [15] [16] [17] The SARS-CoV-2 RBD comprises 193 amino acid residues from Thr333 to Pro527, including RBM 438-506 that interacts directly with ACE2. It contains eight cysteines forming four disulfide bridges, three of these stabilizing the RBD core and one within the RBM. 6 Our recombinant RBD 319-541 was obtained in CHO-cells with intentionally extended sequence adding S-glycoprotein residues 527 through 541, in order to include an additional Cys538. This cysteine is usually connected to Cys590 in the S-glycoprotein. The extended sequence includes two N-glycosylation sites at residues Asn331 and Asn343 and two O-glycosylation sites at Thr323 and Ser325. The selected sequence results in an unpaired Cys538 intended to be used for chemical conjugation to the highly immunogenic carrier tetanus toxoid (TT). Here we report a promising vaccine candidate based on this high molecular weight conjugate with several copies of recombinant RBD per molecular unit. To our knowledge, chemically conjugated constructs and the immunogenic effect of conjugating viral proteins such as RBD to a protein carrier have not been assessed for SARS-CoV-2 or other coronaviruses. Here we demonstrate that the RBD-TT conjugate induces a potent immune response in laboratory animals, paving the way for their evaluation in human phase I and II clinical trials. 18 Our design is based on the hypothesis that by conjugating several copies of the extended RBD to a large carrier protein, we can obtain a macromolecular construct displaying multivalent RBD. At 5 the same time, the RBM will be well exposed (Fig. 1 , represented in red) and more available for immune recognition. Inclusion of an additional free Cys538 in our extended RBD, while potentially useful for conjugation, could jeopardize extended-RBD folding, due to potential S-S rearrangement with the other 8 cysteines (scrambling). Nevertheless, we found that during fermentation and purification, Cys538 is spontaneously protected through an S-S Cys adduct with free cysteine present in the culture media. ESI-MS showed presence of the four native S-S bonds, indicating a correctly folded extended RBD (Fig. S2 ). Cysteinylated Cys538 was selectively reduced to free thiol with tris-(2-carboxyethyl)phosphine (TCEP) 19 without affecting ACE2 recognition, while-for example-dithiothreitol (DTT) led to complete loss of its ACE2 binding capacity, suggesting loss of the antigen's 3D structure (Fig. 1B) . To our knowledge, the immunogenic effect of TT as a carrier has not been assessed previously for SARS-CoV-2 or any other coronavirus. We have successfully used TT as a carrier protein for antibacterial carbohydrate-protein conjugate vaccines. 20, 21 The presence of multiple T-and B-cell epitopes of this highly immunogenic carrier 22 might potentiate cellular immunity when compared to use of RBD alone. In addition, multimeric RBD-TT can simultaneously activate several B-cell receptors, thus enhancing B cell response. 23 TT was activated with an average of 20-30 maleimide groups per mol of TT by reaction with Nsuccinimidyl 3-maleimidopropionate (SMP) followed by reaction with 2.5 or, alternatively, 10 equivalents of TCEP-reduced extended RBD, to produce conjugates bearing 2 or 6 mol, respectively, of RBD per mol of TT (Fig. 1c) . The RBD 2 -TT and RBD 6 -TT conjugates were produced under good manufacturing practices (GMP) in 72% and 64% yield, respectively, and characterized by SE-HPLC and MS. Both conjugates recognize ACE2 slightly better than the 6 original RBD, (Fig. 1E) , confirming preservation of their structure and, probably, a better exposition of RBM. As convalescent serum usually contains TT antibodies, we prepared a RBDbovine serum albumin (BSA) conjugate incorporating 6 RBD units per mol of BSA (RBD 6 -BSA), which was recognized well by various convalescent sera, proving conservation of the RBD antigenic properties after conjugation (Fig. 1D ). Immunization of BALB/c mice with the four different immunogens (Fig. 2) induces a strong IgG RBD-specific immune response as proven by ELISA. RBD 6 -TT/alum and RBD 2 -TT/alum were compared with RBD alone and with RBD 2 -TT without alum. After the first dose (T7 and T14, Fig. 2C ). The high and homogeneous early response for RBD 6 -TT/alum could be an important attribute for a vaccine in pandemic times. We explored early response to different dosage of RBD 6 -TT/alum, finding a dose-dependent response at day 7. At day 14, before the second dose, the response was very high even for the lowest dosage (T14, Fig. 2C ). To evaluate possible immunological advantages of the RBD-TT conjugate, we studied affinity maturation, of antibodies elicited by RBD 6 -TT compared with the rest of immunogens. There was an increase in the avidity index (AI). 24 The highest value of 81% for antibodies induced by RBD 6 -TT is consistent with a more pronounced affinity maturation. (Fig. 2D) . The Th1/Th2 balance can be modulated by vaccination and was also evaluated (Fig. 2E) . A biased Th2 immune response was observed for RBD 2 -TT/alum (IgG2a/IgG1 ratio 0.54) and RBD/alum (IgG2a/IgG1 ratio 0.40), while RBD 6 -TT/alum displayed more balanced Th1/Th2 immunity (IgG2a/IgG1 ratio 0.81). conjugate vaccines. Mice immunized with conjugate RBD 6 -TT/alum were compared to mice receiving RBD/alum. Both groups developed a primary immunity as shown previously (Fig. 2B ). After two doses at T28, splenocytes purified from both groups were intravenously transferred to naïve mice that were then boosted by a single dose of 3 μ g RBD/alum (Fig. 3B) . Mice receiving splenocytes from RBD 6 -TT/alum responded with a strong secondary RBD-specific IgG response ( titer 10 3 -10 4 ), while those receiving splenocytes from RBD/alum did not (results not shown). This finding demonstrated the presence of RBD-specific memory B cells in transferred splenocytes, which were able to be activated in the presence of RBD/alum (alternative SARS-CoV-2 virus) stimuli. Specific CD8+ T cells also play an important role in protection, as recently demonstrated. 25 To evaluate the specific T-cell response, we compared RBD 6 -TT/alum and RBD/alum immunized mice. After in vitro RBD stimuli, splenocytes from mice immunized with RBD 6 -TT secreted higher levels of IFNγ compared to those immunized with RBD/alum (Fig. 3D) , suggesting a Th1 pattern, while IL-4 (characteristic of Th2 pattern) and IL-17A (characteristic of Th17 pattern) were not detected. Frequency of CD8 + CD44 high memory T-lymphocytes producing IFN-γ, TNF-α and Granzyme B increased significantly in RBD 6 -TT immunized mice with respect to control mice (Fig. 3E) as shown by flow cytometry, indicating the relevant activation of cytotoxic T immune memory. 8 We evaluated antibodies' ability to block interaction between the virus and its receptor, 10 using the molecular Virus Neutralization Test (mVNT50) 22 Test (cVNT50). 23 mVNT50 evaluates inhibition of interaction between recombinant RBD and ACE2 at the molecular level; at the cellular level, cVNT50 evaluates inhibition of interaction between the live virus and Vero E6 cells bearing ACE2 receptors. Antibodies resulting from immunization of Balb/c mice with two doses of RBD 2 -TT/alum and RBD 6 -TT/alum were compared to antibodies elicited after immunization with RBD/alum. mVNT50 showed a high level of inhibition for all sera (Fig. 4a ), indicating that all tested antibodies displayed a similar efficacy in interfering with RBD-ACE2 interaction at the molecular level. cVNT50 (Fig. 4B) showed sharp differences between sera from animals immunized with RBD/alum and those with both conjugates. For RBD/alum, the neutralization titer was 232; for both conjugates, there was a higher level of virus neutralization: 1303 for RBD 2 -TT and 2568 for RBD 6 -TT. The mVNT50/cVNT50 ratio was 0.143, 0.732 and 1.08 for RBD, RBD 2 -TT and RBD 6 -TT respectively. While antibodies neutralizing the virus are mainly directed at the RBM, 7 there are antibodies recognizing soluble RBD not only by the RBM but also on a different region, as shown in Fig. 4C . This type of "lateral" antibodies could interfere in mVNT50 with soluble RBD, but probably will not recognize this RBD region that is camouflaged at the virus surface. Based on the results presented here, GMP batches of the conjugates RBD 2 -TT and RBD 6 -TT were obtained and absorbed on alum as final vaccine candidates. A phase I clinical trial 24 was initiated in October 2020, and after preliminary results confirming a better performance of a vaccine based on RBD 6 -TT/alum, this advanced on December 2020 to a phase II clinical trial with 910 subjects. 25 The encouraging interim results of all those trial envisage moving forward to a phase III trial in March 2021. The resulting vaccine, the first one developed and produced in a Latin-American country, has important advantages to be considered in the future: a) it induces a strong IgG neutralizing antibody as well as specific T-cell response, b) the well-known safety record of this vaccine platform is further confirmed during clinical trial, c) the storage and distribution temperature of 2-8 o C is the conventional for other vaccines and suitable for a rapid distribution worldwide, and finally, d) it can be adapted to existing vaccine production capacities available at several countries. We hope this vaccine can contribute to win the battle against the SARS-CoV-2 pandemic. 1 1 vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572-577 (2020). Clinical trial phase II NCT04718467, Clinical trial phase II RPCEC00000306, Clinical trial phase I NCT04522089. The representing the serum dilution giving 50% inhibition ACE2-RBD interaction. (B) cVNT 50 measured as serum dilution giving 50% of virus neutralization (C) mVNT50/cVNT50 ratio and a possible schematic representation of the differences found. SARS-CoV-2 vaccines in development Structure analysis of the receptor binding of 2019-nCoV Structural basis of receptor recognition by SARS-CoV-2 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic Immunological considerations for COVID-19 vaccine strategies First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. medRxiv Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model Structural basis of a shared antibody response to SARS-CoV-2 Potently neutralizing and protective human antibodies against SARS-CoV-2 New watersoluble phosphines as reductants of peptide and protein disulfide bonds: reactivity and membrane permeability A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial Protein carriers of conjugate vaccines: characteristics, development, and clinical trials Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization Correlates of protection against SARS-CoV-2 in rhesus macaques A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction We thank Rolando Pérez, Luis Herrera, Agustin Lage and Eduardo Martinez (BioCubaFarma), for advice and support to the project, Lila Castellanos and Gail Reed for editing English version; as well as the Fondo de Ciencia e Innovacion (FONCI) for financial support (Project-2020-20).We are grateful to the Leibniz Institute of Plant Biochemistry, Germany, for support in structural characterization. All authors revised the manuscript and approved submission.